Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Alvopetro Announces Year End 2025 Financial Results, Q1 2026 Dividend of US$0.12/share, and Filing of our AIF
QIMC Reports Results from Hole 1 DDH-26-01 at West-Advocate Natural Hydrogen Project, Nova Scotia; R2G2(TM) Exploration Model Applied
